Core Viewpoint - Spectral AI, Inc. has announced a 30% increase in its patent portfolio, enhancing its proprietary AI-driven DeepView System for wound assessment, which aims to improve treatment decisions in wound care [4][5]. Patent Portfolio - The total patents granted to the Company increased to 26 as of July 8, 2024, from 20 at December 31, 2023, comprising 12 U.S. patents and 14 international patents [2][4]. - The Company has an additional 38 pending patent applications worldwide, including seven pending U.S. patents and 31 international patents, covering nine distinct patent families [9]. Technology and Applications - The DeepView System utilizes multi-spectral imaging and machine learning to provide objective assessments of wound healing potential, particularly for patients with burns and diabetic foot ulcers [6]. - The technology aims to revolutionize wound care management by offering faster and more accurate treatment insights, ultimately improving patient outcomes and reducing healthcare costs [6]. Future Plans - The Company plans to commence product commercialization initiatives in late 2024, continuing through 2026, leveraging its intellectual property assets as a foundation for success [5].
Spectral AI Announces Total U.S. and International Patent Portfolio Now Stands at 26 Granted Patents and 38 Pending Applications in Support of its AI-Driven DeepView System